Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 17/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 6/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429049 | 0.83 | MAOB (0.67) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL933047 | 0.82 | MAOB (0.61) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL29773892 | 0.79 | ALDH1A1 (0.53) | ALDH1A1CYP3A4HPGDPPARD | |
| SCHEMBL27097925 | 0.79 | ALDH1A1 (0.53) | ALDH1A1CYP3A4HPGDPPARD | |
| SCHEMBL10694407 | 0.79 | MAOB (0.46) | MAOBALDH1A1HPGDMAPK1HTT | |
| SCHEMBL28512267 | 0.78 | NPC1 (0.43) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL103360 | 0.77 | MAPT (0.65) | MAOBALDH1A1HPGDMAOAMAPT | |
| SCHEMBL1180883 | 0.77 | ALDH1A1 (0.67) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL30231667 | 0.77 | MAOB (0.71) | MAOBALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL5711594 | 0.77 | MAOB (0.74) | MAOBALDH1A1CYP3A4HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-04-21 | — | — | US | disclosed |
| EP-3848367-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-07-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119376-A1 | TRICYCLIC COMPOUNDS ACTING ON CRBN PROTEINS | CRBN, CSNK2A1, CSNK2A2 | MAOB 3428/4885ALDH1A1 4087/4885CYP3A4 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.